Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform

An insightful and informative discussion on the Genetic Engineering News podcast "Touching Base", highlights recent advances for Iambic's clinical oncology candidate IAM1363, as well as its AI drug-discovery models and ongoing technical collaborations and drug development efforts.

Announcements

This is some text inside of a div block.

April 8, 2024

Media Contacts

Related announcements

View All

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors

Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors